EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Total-body [11C]carfentanil PET: Liver-brain axis in methadone vs. buprenorphine treatment

Elizabeth J Li, Corinde E Wiers, Chia-Ju Hsieh, Hsiaoju Lee, Alexander Schmitz, Anthony J Young, Timothy Pond, Joseph Chang, Erin K Schubert, Robert H Mach, Henry R Kranzler, Jacob G Dubroff

European Journal of Nuclear Medicine and Molecular Imaging · 2026-11 · 53 (13) · 7898-7909

DOI: 10.1007/s00259-026-08144-2 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 22.08.2026. Verfasst von Elizabeth J Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA. Hauptthemen laut MEDLINE: Buprenorphine, Positron-Emission Tomography, Methadone, Fentanyl. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDA NIH HHS, National Institute on Drug Abuse.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To examine the relationship between brain mu opioid receptor (MOR) availability and liver activity in opioid use disorder (OUD) patients treated with methadone (MET) or buprenorphine (BUP).

Methods

10 OUD patients, 5 treated with MET and 5 with BUP, as well as 13 healthy controls (HCs) underwent total-body PET [ 11 C]carfentanil (CFN) imaging. MOR availability was quantified using distribution volume ratio (DVR) in key MOR-rich brain regions, and hepatic distribution volume (Vt) was used as an index of systemic tracer pharmacokinetics. Serum drug levels were measured in the OUD patients.

Results

Brain MOR availability was significantly lower in the OUD groups relative to HCs (p < 0.001), more so in BUP-treated (mean MOR difference = 39.9 ± 15.9%, Cohen’s d = 3.35) than MET-treated (mean MOR difference = 14.2 ± 9.9%, d = 1.90) patients. Central MOR availability was inversely related to serum drug levels, linearly in MET treated (R2 = 0.83) and logarithmically in BUP-treated (R2 = 0.96), consistent with distinct receptor occupancy dynamics. Hepatic Vt differed across groups (p < 0.003) with levels in both OUD groups lower than in HCs (p < 0.05). In MET-treated patients, hepatic Vt was strongly associated with brain MOR availability (R 2 = 0.68), and inversely associated with serum drug levels (R 2 = 0.63). This relationship was less pronounced in BUP-treated patients (R 2 = 0.30), and absent in HCs.

Conclusions

Drug-specific, brain-liver pharmacokinetic profiles were observed in OUD patients treated with MET versus BUP. While MET patients demonstrated coupling between hepatic tracer kinetics and brain receptor occupancy, BUP patients did not. These findings demonstrate that drug-specific brain-body pharmacokinetics may underscore observed clinical differences in opioid agonist effects in OUD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BuprenorphinePositron-Emission TomographyMethadoneFentanylBrainLiverOpioid-Related DisordersWhole Body ImagingHumansFemaleMaleAdultCarbon RadioisotopesReceptors, Opioid, muMiddle Aged

Stichwörter der Autor:innen

BuprenorphineMethadoneMu-opioid receptorsOpioid use disorderTotal-body positron emission tomography[11C]carfentanil

Substanzen

BuprenorphineMethadoneFentanylcarfentanilCarbon RadioisotopesReceptors, Opioid, muCarbon-11

Autor:innen und Institutionen

  • Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
  • Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
  • Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA. kranzler@pennmedicine.upenn.edu.
  • Mental Illness Research, Education and Clinical Center, Crescenz VAMC, Philadelphia, PA, 191 04, USA. kranzler@pennmedicine.upenn.edu.
  • Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA. jacob.dubroff@pennmedicine.upenn.edu.

Förderung

  • NIDA NIH HHS
  • National Institute on Drug Abuse

Zitieren

APA

Li, E. J., Wiers, C. E., Hsieh, C. J., Lee, H., Schmitz, A., Young, A. J., Pond, T., Chang, J., Schubert, E. K., Mach, R. H., Kranzler, H. R., & Dubroff, J. G. (2026). Total-body [11C]carfentanil PET: Liver-brain axis in methadone vs. buprenorphine treatment. European Journal of Nuclear Medicine and Molecular Imaging, 53(13), 7898-7909. https://doi.org/10.1007/s00259-026-08144-2

Vancouver

Li EJ, Wiers CE, Hsieh CJ, Lee H, Schmitz A, Young AJ, et al. Total-body [11C]carfentanil PET: Liver-brain axis in methadone vs. buprenorphine treatment. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(13):7898-7909. doi:10.1007/s00259-026-08144-2

BibTeX
@article{Li2026,
  author = {Li, Elizabeth J and Wiers, Corinde E and Hsieh, Chia-Ju and Lee, Hsiaoju and Schmitz, Alexander and Young, Anthony J and Pond, Timothy and Chang, Joseph and Schubert, Erin K and Mach, Robert H and Kranzler, Henry R and Dubroff, Jacob G},
  title = {Total-body [11C]carfentanil PET: Liver-brain axis in methadone vs. buprenorphine treatment},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  volume = {53},
  number = {13},
  pages = {7898--7909},
  doi = {10.1007/s00259-026-08144-2}
}
Kostenlos starten →